Adjuvant Hormonal Therapy for Premenopausal Women With Breast Cancer

Seminars in Oncology

Volumn 33, Issue 6, 2006, Pages 657-663

  Brown, Regina J ^a   Davidson, Nancy E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; METHOTREXATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE; TRIPTORELIN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; AMENORRHEA; ARTICLE; BONE ATROPHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; EARLY MENOPAUSE; FEMALE INFERTILITY; FEMALE SEXUAL DYSFUNCTION; HOT FLUSH; HUMAN; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PREGNANCY COMPLICATION; PREMENOPAUSE; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; RISK REDUCTION; SURGICAL RISK; TREATMENT OUTCOME; VAGINAL DRYNESS;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; OVARIECTOMY; PREMENOPAUSE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 37549001360     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.08.014     Document Type: Article

References (37)

1. Osborne C.K. Adjuvant endocrine therapy. In: Harris J.R., Lippman M.E., Morrow M., et al. (Eds). Diseases of the Breast. (ed 3) (2004), Williams, & Wilkins, Philadelphia, PA, Lippincott 865-891
2. Emens L.A., and Davidson N.E. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 9 (2003) 486S-494S
3. Dellapasqua S., Colleoni M., Gelber R.D., et al. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23 (2005) 1736-1750
4. Visvanathan K., and Davidson N.E. Adjuvant endocrine therapy: Controversies and perspectives. In: Bonadonna G., Hortobagyi G.N., and Valagussa P. (Eds). Textbook of Breast Cancer. A Clinical Guide to Therapy. (ed 3) (2006), Taylor & Francis, New York, NY 205-223
5. Fabian C.J., and Kimler B.F. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 23 (2005) 1644-1655
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of randomized trials. Lancet 365 (2005) 1687-1717
7. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 30 (2001) 5-15
8. Beatson G.W. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2 (1896) 104-107
9. Domchek S.M., Friebel T.M., Neuhausen S.L., et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncol 7 (2006) 191-193
10. Hughes L.L., Gray R.J., Solin L.F., et al. Efficacy of radiotherapy for ovarian ablation: Results of a breast intergroup study. Cancer 101 (2004) 969-972
11. Petrek J.A., Naughton M.J., Case L.D., et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 24 (2006) 1045-1051
12. Parulekar W.R., Day A.G., Ottaway J.A., et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol 23 (2005) 6002-6008
13. Aebi S., Gelber S., Castiglione-Gertsch M., et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet 355 (2000) 1869-1874
14. Fornier M.N., Modi S., Panageas K.S., et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104 (2005) 1575-1579
15. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 (2005) 2302-2313
16. Robertson J.F., and Blamey R.W. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 39 (2003) 861-869
17. Kaufmann M., Jonat W., Blamey R., et al. Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39 (2003) 1711-1717
18. Thomson C.S., Twelves C.J., Mallon E.A., et al. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast 11 (2002) 419-429
19. Schmid P., Untch M., Wallwiener D., et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res 22 (2002) 2325-2332
20. Castiglione-Gertsch M., O'Neill A., Price K.N., et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 95 (2003) 1833-1846
21. Ejlertsen B, Mouridsen HT, Jensen M-B, et al: Ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: Similar efficacy from a randomized comparison in premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol (in press)
22. Boccardo F., Rubagott A., Amoroso E., et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18 (2000) 2718-2727
23. Roche H., Kerbrat P., Bonneterre J., et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol 17 (2006) 1221-1227
24. Roche H., Mihura J., de Lafontan B., et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptor positive breast cancer patients: A randomized trial with a 7 year median followup. Proc Am Soc Clin Oncol 15 (1996) 117 (abstr)
25. Jakesz R., Hausmaninger H., Kubista E., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group 5. J Clin Oncol 20 (2002) 4621-7462
26. Davidson N.E., O'Neill A.M., Vukov A.M., et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol 23 (2005) 5973-5982
27. Arriagada R., Le M.G., Spielmann M., et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 16 (2005) 389-396
28. Baum M., Hackshaw A., Houghton J., et al. Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 42 (2006) 895-904
29. Love R.R., Duc N.B., Allred D.C., et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20 (2002) 2559-2566
30. Love R.R., Duc N.B., Havighurst T.C., et al. Her-2neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21 (2003) 453-457
31. Robert N., Wang M., Wood W., et al. Phase III comparison of tamoxifen with ovarian ablation in premenopausal women with axillary node negative receptor positive breast cancer <3 cm. Proc Am Soc Clin Oncol 22 (2003) 16a (abstr)
32. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
33. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
34. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
35. Thewes B., Meiser B., Taylor A., et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Ocnol 23 (2005) 5155-5165
36. Partridge A.H., Gelber S., Peppercorn J., et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22 (2004) 4174-4183
37. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal breast cancer: Status report 2004. J Clin Oncol 23 (2005) 619-629